Should titration schedules for cholinesterase inhibitors be changed?

International Journal of Geriatric Psychiatry

Volumn 18, Issue 11, 2003, Pages 1063-1064

  Sikdar, Sudip ^a  

^a UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

ALZHEIMER DISEASE; CLINICAL TRIAL; CONSULTATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG WITHDRAWAL; HUMAN; LETTER; LONG TERM CARE; MAXIMUM TOLERATED DOSE; PRESCRIPTION; SIDE EFFECT; TABLET; TREATMENT PLANNING;

ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PATIENT COMPLIANCE;

EID: 0344098999     PISSN: 08856230     EISSN: None     Source Type: Journal    
DOI: 10.1002/gps.996     Document Type: Letter

References (3)

1. Rosler M, Anand R, Cicin-Sain A, et al. 1999. Efficacy and safety of rivastigmine in-patients with Alzheimer's disease: International randomized controlled trial. BMJ 318: 633-640.
2. Inglis F. 2002. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 127: 45-63.
3. Anand R, Hartman R, Sohn H, et al. 2003. Impact of study design and patient population on outcomes from cholinesterase inhibitor trials. Am J Geriatr Psychiatry 11: 160-168.